^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    nanoparticle-actinomycin D (NP-ACT D)

    i
    Other names: NP-ACT D, RASP-101
    Associations

    News

    Trials
    Company:
    Rasna Therap, Tiziana Life Sci
    Drug class:
    Topoisomerase II inhibitor, RNA synthesis inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    Albumin pre-opsonized membrane-active iPep nanomedicine potentiates chemo to immunotherapy of cancer. (PubMed, Biomaterials)
    In a challenging orthotopic breast cancer model, boost i. v. injections of NP acted as in situ tumor vaccine that drastically enhanced 4T1-specific cellular and humoral immunities to reverse disease progression. Thus, with combined effects of direct cytoreduction, immune activation and tumor vaccine, iPep-NP presents the promise and potential of a new modality of cancer medicine.
    Journal
    |
    nanoparticle-actinomycin D (NP-ACT D)